Summary of AML cases
| Characteristic . | Case 1 . | Case 2 . |
|---|---|---|
| Age, y | 71 | 68 |
| Performance status (ECOG) | 1 | 2 |
| WHO/FAB Dx | AML M0 | AML M2 |
| Prior AML therapy | No | FLAG chemotherapy at original presentation |
| Duration of prior remission | N/A | 3.5 y |
| Lenalidomide treatment | ||
| Cycle 1 | 50 mg/d, days 1-14; no therapy × 30 d | 35 mg/d, days 1-21 |
| Cycle 2 | 50 mg/d × 21 d; no therapy × 30 d | 35 mg days 1-4 (therapy halted due to pneumonia) |
| Cycle 3 | 35 mg days 1-21 | |
| Cycle 4 | (start of cycle delayed 3 wk until resolution of grade 2* neutropenia and thrombocytopenia) 35 mg days 1-21 | |
| Low-dose cycles | 10 mg/d, days 1-28, × 5; then low-dose therapy 10 mg/d, ongoing | |
| Prelenalidomide data | ||
| White blood cells | 1900/μL | 1700/μL |
| Hemoglobin | 6.7 g/dL | 9.3 g/dL |
| Platelets | 74 000/μL | 45 000/μL |
| ANC | 190/μL | 530/μL |
| PB blast | 363/μL (33%) | 0/μL |
| BM cellularity | 30% | 40% |
| BM blasts | 90% | 40% |
| Karyotype | 47,XY,+13[5]/46,XY[15] | 94<4n>,XXYY,+13,+13(cp15)/46,XY(3)/nonclonal(2) |
| Data at CR | ||
| Days to CR | 124 (35 d of high-dose therapy, 28 d of low-dose therapy) | 78 (25 d of treatment) |
| White blood cells | 6100/μL | 7500/μL |
| Hemoglobin | 10.1 g/dL | 8.6 g/dL |
| Platelets | 231 000/μL | 210 000/μL |
| ANC | 4148/μL | 4275/μL |
| BM cellularity | 60% | 40% |
| BM blast | < 5% | <5% |
| Duration of CR | 9 mo | 9 mo |
| CR confirmation | Yes (6 wk, 16 wk) | Yes (5 wk) |
| Characteristic . | Case 1 . | Case 2 . |
|---|---|---|
| Age, y | 71 | 68 |
| Performance status (ECOG) | 1 | 2 |
| WHO/FAB Dx | AML M0 | AML M2 |
| Prior AML therapy | No | FLAG chemotherapy at original presentation |
| Duration of prior remission | N/A | 3.5 y |
| Lenalidomide treatment | ||
| Cycle 1 | 50 mg/d, days 1-14; no therapy × 30 d | 35 mg/d, days 1-21 |
| Cycle 2 | 50 mg/d × 21 d; no therapy × 30 d | 35 mg days 1-4 (therapy halted due to pneumonia) |
| Cycle 3 | 35 mg days 1-21 | |
| Cycle 4 | (start of cycle delayed 3 wk until resolution of grade 2* neutropenia and thrombocytopenia) 35 mg days 1-21 | |
| Low-dose cycles | 10 mg/d, days 1-28, × 5; then low-dose therapy 10 mg/d, ongoing | |
| Prelenalidomide data | ||
| White blood cells | 1900/μL | 1700/μL |
| Hemoglobin | 6.7 g/dL | 9.3 g/dL |
| Platelets | 74 000/μL | 45 000/μL |
| ANC | 190/μL | 530/μL |
| PB blast | 363/μL (33%) | 0/μL |
| BM cellularity | 30% | 40% |
| BM blasts | 90% | 40% |
| Karyotype | 47,XY,+13[5]/46,XY[15] | 94<4n>,XXYY,+13,+13(cp15)/46,XY(3)/nonclonal(2) |
| Data at CR | ||
| Days to CR | 124 (35 d of high-dose therapy, 28 d of low-dose therapy) | 78 (25 d of treatment) |
| White blood cells | 6100/μL | 7500/μL |
| Hemoglobin | 10.1 g/dL | 8.6 g/dL |
| Platelets | 231 000/μL | 210 000/μL |
| ANC | 4148/μL | 4275/μL |
| BM cellularity | 60% | 40% |
| BM blast | < 5% | <5% |
| Duration of CR | 9 mo | 9 mo |
| CR confirmation | Yes (6 wk, 16 wk) | Yes (5 wk) |
WHO indicates World Heath Organization; ECOG, Eastern Cooperative Oncology Group; Dx, diagnosis; ANC, absolute neutrophil count; PB, peripheral blood; BM, bone marrow; and CR, complete remission.
Toxicity graded by National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0.